review glp 1 Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide Receptor Agonists: A Scoping glp-1 review GLP-1 Drug Savings:

At the 9mg dose, 8.8% of participants experienced dysesthesia

doi: 10.1080/14656566.2019.1688784 [DOI] [PubMed] [Google Scholar] 45

Studies show that 98% of GI events with semaglutide were "mild-to-moderate and transient," mostly occurring during or shortly after dose increases

FDA has given these companies a facility-dependent grace period of 60 to 90 days to stop selling compounded GLP-1 drugs before the agency takes enforcement action, aiming to avoid unnecessary disruptions in patient care

What it does support is something more basic: womens physiology spent decades on the sidelines of clinical research, and were still filling in the gaps

Insurance Not typically covered